Foundation Medicine (FMI) Tops Q4 EPS by 4c

Go back to Foundation Medicine (FMI) Tops Q4 EPS by 4c

Wedbush Downgrades Foundation Medicine (FMI) to Neutral

February 25, 2015 6:48 AM EST

Wedbush downgraded Foundation Medicine (NASDAQ: FMI) from Outperform to Neutral with a price target of $45.00 on valuation and limited upside to numbers near-term.

Analyst Zarak Khurshid commented, "We believe the lack of meaningful upside to numbers (see our below consensus estimates) plus... More